Prostate最新文献

{"title":"Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer.","authors":"Cem Onal, Ozan Cem Guler, Gurcan Erbay, Birhan Demirhan, Aysenur Elmali, Melek Yavuz","doi":"10.1002/pros.24888","DOIUrl":"10.1002/pros.24888","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the impact of radiotherapy (RT) with or without a simultaneous integrated boost (SIB) to intraprostatic lesions on survival, recurrence, and toxicity in localized prostate cancer (PCa). Key prognostic and predictive factors were also analyzed.</p><p><strong>Materials and methods: </strong>A retrospective analysis included 712 intermediate- and high-risk PCa patients treated with external beam RT at 78 Gy, with or without SIB (up to 86 Gy), between 2010 and 2018. Propensity score matching (PSM) was used to ensure comparability. Outcomes assessed included biochemical disease-free survival (bDFS), prostate cancer-specific survival (PCSS), local recurrence (LR), distant metastasis (DM), and treatment-related toxicities.</p><p><strong>Results: </strong>After PSM, 417 patients were analyzed (208 with SIB, 209 without). Over a median follow-up of 8.6 years, the SIB group showed higher 8-year bDFS (93.8% vs. 83.5%; p = 0.006) and lower rates of DM (6.1% vs. 13.0%; p = 0.003) and LR (1.8% vs. 6.9%; p = 0.03). PCSS was similar between groups (95.7% vs. 92.3%; p = 0.38). Advanced T stage and absence of SIB were predictors of worse bDFS, DM, and LR, while higher Gleason score were associated with poorer PCSS and DM in multivariable analysis. There were no significant differences in 8-year Grade ≥ 2 GU (10.1% vs. 10.5%; p = 0.98) or GI (7.8% vs. 6.5%; p = 0.64) toxicities between the SIB and non-SIB groups.</p><p><strong>Conclusions: </strong>SIB with external beam RT significantly improves bDFS and reduces LR and DM in intermediate- and high-risk PCa, with no increase in significant toxicities. These findings emphasize the value of dose escalation in achieving better local control and long-term outcomes while maintaining patient safety.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"805-813"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET.","authors":"Baris Esen, Hulya Seymen, Ayşe Armutlu, Ersin Koseoglu, Ibrahim Can Aykanat, Hatice Zoroğlu, Abdullah Erdem Canda, Yakup Kordan, Mevlana Derya Balbay, Dilek Ertoy Baydar, Mehmet Onur Demirkol, Derya Tilki, Tarık Esen","doi":"10.1002/pros.24884","DOIUrl":"10.1002/pros.24884","url":null,"abstract":"<p><strong>Background: </strong>PSMA PET/CT has previously shown superior performance in nodal staging of prostate cancer (PCa) and may be used to reduce the number of unnecessary PLND procedures. This study aims to assess the performance of PSMA PET/CT in nodal staging of intermediate-risk prostate cancer and to evaluate the effect of PLND on oncological outcomes of intermediate-risk prostate cancer patients with a negative PSMA PET/CT.</p><p><strong>Methods: </strong>A total of 308 patients with intermediate-risk PCa who underwent PSMA PET/CT for nodal staging between January 2014 and July 2024 were included in the study. Patients who underwent PLND had higher PSA and higher rates of PIRADS-5 and biopsy grade-group 3 disease. A 1:1 propensity score matching was performed to eliminate patient characteristics differences between groups and 140 patients were included in the final analysis. PSA persistence rates ( ≥ 0.1 ng/dL) and biochemical recurrence (BCR; ≥ 0.2 ng/dL) rates after RP were recorded. Kaplan-Meier curves were constructed to evaluate oncological outcomes. Log-rank test was utilized to compare oncological outcomes in patients with and without PLND.</p><p><strong>Results: </strong>The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PSMA PET/CT on nodal staging were 53.3%, 95%, 47.1%, and 96.1%, respectively. The NPV of PSMA PET/CT in patients with biopsy GG3 disease (96.3%) was similar to those with biopsy GG2 disease (95.6%). The median follow-up after propensity score matching was 20.7 months. The 24-month BCR-free survival rates were 83.7% and 86.9% in the PLND-RP group and RP-only groups, respectively (p = 0.078).</p><p><strong>Conclusions: </strong>NPV of PSMA PET/CT in determining LNI was remarkable in patients with intermediate-risk PCa and PLND was found to have no impact on oncological outcomes. Therefore PLND may be omitted to decrease surgery-related complications in patients with intermediate-risk PCa a negative PSMA PET/CT for nodal staging.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"777-783"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Enzalutamide-Resistance Based on a Functional Single-Cell Approach.","authors":"Changhui Xue, Hyun-Kyung Ko, Kasen Shi, Janet Pittsenbarger, Lucien Vu Dao, Kaiyo Shi, Maximilian Libmann, Hao Geng, David Z Qian","doi":"10.1002/pros.24895","DOIUrl":"https://doi.org/10.1002/pros.24895","url":null,"abstract":"<p><strong>Background: </strong>Anti-androgen or castration therapies are the mainstay treatment for metastatic prostate cancers (PCa). Although effective at first, androgen-dependent PCa (ADPC) universally develops therapy resistance, thereby evolving into an incurable disease called castration-resistant PCa (CRPC). Currently, mechanisms underlying the emergence of CRPC from ADPC are largely unclear.</p><p><strong>Methods: </strong>We used single-cell RNA-sequencing (scRNA-Seq) to determine the transcription heterogeneity of a therapy-naïve ADPC cell line-LNCaP and how it responded to the anti-androgen drug, enzalutamide. Based on the results, we used single-cell/colony-based cloning to isolate a pre-enzalutamide cell subset, displaying low and/or no expression of androgen receptor (AR^low/-).</p><p><strong>Results: </strong>We found that most LNCaP cells expressed enzalutamide-target androgen receptor (AR+), while a small subpopulation (~10%) expressed low or no AR (AR^low/-). Gene set enrichment analysis (GSEA) revealed that AR⁺ and AR^low/- cells were enriched with significantly different gene expressions and signaling pathways. Unexpectedly, AR^low/- cells displayed robust transcriptional response, including upregulations of genes and pathways involved in clinical CRPC. Next, we isolated AR^low/- and AR⁺ cells from enzalutamide-naïve LNCaP cells and functionally confirmed the enzalutamide-resistant phenotype of AR^low/- cells in vitro and in xenograft models in vivo. Through xenograft-based single-nucleus RNA-Seq, we further found that the AR^low/- cells were selected, while the AR⁺ cells were de-selected in vivo by enzalutamide. Also, we found that the selection and expansion of AR^low/- clone were recapitulated in another enzalutamide-resistant cell model.</p><p><strong>Conclusion: </strong>In summary, our single-cell-based sequencing and functional tests suggest a clonal selection and expansion model of enzalutamide resistance, in which the pretreatment AR-low subpopulation is selected and expanded to confer treatment resistance.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":"85 9","pages":"888-899"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis.","authors":"Kotaro Suzuki, Junichiro Hirata, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake","doi":"10.1002/pros.24889","DOIUrl":"10.1002/pros.24889","url":null,"abstract":"<p><strong>Background: </strong>Cabazitaxel (CBZ) is a key drug used for metastatic castration-resistant prostate cancer (mCRPC). However, clinical trial data on CBZ in very elderly patients are still lacking. This study aimed to investigate the efficacy and feasibility of CBZ for mCRPC patients of ≥ 80 years of age.</p><p><strong>Methods: </strong>We retrospectively reviewed 484 patients with mCRPC who started CBZ treatment between September 2019 and March 2024. Therapeutic efficacy (PSA response, progression-free survival, overall survival, and safety profile) was compared between patients of < 80 years of age (< 80 group) and those of ≥ 80 years of age (≥ 80 group). In addition, risk factors associated with grade ≥ 3 neutropenia in the ≥ 80 group were investigated using a logistic regression model.</p><p><strong>Results: </strong>Seventy-three (15.1%) patients were included in the ≥ 80 group. Although more patients in the ≥ 80 group received a reduced dose relative to the < 80 group, there was no significant difference in therapeutic efficacy between the two groups. The incidence of grade ≥ 3 neutropenia was similar between two groups (< 80: 27.5% vs. ≥ 80: 31.5%). In the ≥ 80 group, BMI < 22 kg/m² and neutrophil count ≤ 5000 cells/µL were significantly associated with grade ≥ 3 neutropenia, with odds ratios of 5.28 (p = 0.005) and 4.00 (p = 0.023), respectively.</p><p><strong>Conclusion: </strong>In mCRPC patients of ≥ 80 years of age, CBZ showed similar safety and efficacy to younger patients. Our findings suggest that CBZ treatment with appropriate dose modification and prophylactic AE treatments may be still beneficial for elderly mCRPC patients in the current aging population.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"814-820"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.","authors":"Mark Willy L Mondia, Prem P Batchala, Robert Dreicer, Michael E Devitt, Matthew R McCord, Melike Mut, Jason P Sheehan, David Schiff, Camilo E Fadul","doi":"10.1002/pros.24890","DOIUrl":"10.1002/pros.24890","url":null,"abstract":"<p><strong>Background: </strong>Brain metastases (BMETS) from prostate cancer are rare. Hence, brain imaging in neurologically asymptomatic patients with advanced prostate cancer (aPC) is not routinely performed. Prostate-specific membrane antigen (PSMA) PET/CT uses a radiotracer that binds to prostate cancer epithelial cells and is FDA-approved for initial staging for high-risk prostate cancer, detecting prostate cancer recurrence, and determining eligibility for radionuclide therapy.</p><p><strong>Methods: </strong>We report six patients with asymptomatic BMETS from aPC found on staging PSMA PET/CT or MRI. Along with cranial MRI, PSMA PET/CT may be useful for detecting asymptomatic intracranial metastasis in select patients with prostate cancer.</p><p><strong>Results: </strong>Brain metastases were diagnosed in four patients by staging PSMA PET/CT scan-three after systemic disease progression and one during routine surveillance. In two other patients, BMETS were detected using MRI despite negative PSMA PET/CT for brain lesions. All were neurologically asymptomatic. Three patients had undetectable serum prostate-specific antigen (PSA) concentrations; one had neuroendocrine differentiation on histology.</p><p><strong>Conclusion: </strong>In patients with poorly differentiated or neuroendocrine aPC, BMETS may occur without neurologic symptoms and stable PSA. PSMA PET/CT may complement brain MRI for identifying BMETS in these patients.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"841-849"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models.","authors":"Haotian Chen, Bairen Pang, Zhihan Liu, Benjie Li, Qi Wang, Baokun Fan, Meng Han, Jie Gong, Cheng Zhou, Yingzhi Chen, Yong Li, Junhui Jiang","doi":"10.1002/pros.24879","DOIUrl":"10.1002/pros.24879","url":null,"abstract":"<p><strong>Background: </strong>Current diagnostic tools are inaccurate and not specific to prostate cancer (PCa) diagnosis. Cancer-derived small extracellular vehicles (sEVs) play a key role in intercellular communication. In this study, we examined the diagnostic value of plasma sEV-derived carbonic anhydrase IX (CAIX) protein for PCa and clinically significant prostate cancer (csPCa) diagnosis and avoiding unnecessary biopsies.</p><p><strong>Methods: </strong>Plasma samples (n = 230) were collected from the patients who underwent prostate biopsy with elevated prostate-specific antigen (PSA) levels. sEVs were isolated and characterized, and sEV protein CAIX was measured using an enzyme-linked immunosorbent assay. Independent predictors of csPCa (Gleason score ≥ 7) were identified, and a predictive model was established. A Nomogram for predicting csPCa was developed using data from the training cohort.</p><p><strong>Results: </strong>The expression of sEV protein CAIX was significantly higher in both PCa and csPCa compared to benign patients and nonsignificant PCa (nsPCa) (Gleason score < 7, p < 0.001). sEV protein CAIX performed well in distinguishing PCa from benign patients. The predictive model defined by sEV protein CAIX and PSA density (PSAD) demonstrated the highest discriminative ability for csPCa (AUC = 0.895), with diagnostic sensitivity and specificity of 82.5% and 85.8%, respectively. Furthermore, sEV protein CAIX is an effective predictor of 2-year biochemical recurrence (BCR) in PCa patients (p = 0.013), and its high expression is significantly associated with poorer BCR-free survival (p < 0.05).</p><p><strong>Conclusions: </strong>Our findings demonstrate the excellent performance of sEV protein CAIX in PCa and csPCa diagnosis. The Nomogram-based csPCa predictive model incorporating sEV protein CAIX and PSAD exhibits strong predictive value. Additionally, assessing plasma sEV protein CAIX expression levels can further aid in evaluating patient prognosis and provide a basis for making effective treatment decisions.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"723-741"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients.","authors":"Rohit V Mantena, Rishabh Bhadouriya, Urvish Jain, Tej A Patel, Bhav Jain, Aditya Arkalgud, Alessandro Hammond, Stephanie Wang, Khushi Kohli, Ranvir Iyengar, Perisa Ashar, Siddharth Kesiraju, Alexander G Goglia, Roshal R Patel, Mohammed Alshalalfa, Jonathan E Leeman, Paul L Nguyen, Brandon A Mahal, Edward Christopher Dee","doi":"10.1002/pros.24887","DOIUrl":"10.1002/pros.24887","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Higher rates of radiation therapy (RT) noncompletion may be associated with certain demographic groups in patients with prostate cancer (PC). We examined disparities in noncompletion and receipt of shorter RT regimens among disaggregated Asian American and Pacific Islander groups in the US.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We performed a retrospective cohort analysis of all patients diagnosed with localized PC (2004-2017) in the National Cancer Database who identified as White, East Asian, Southeast Asian, Pacific Islander, or South Asian who were treated with definitive RT. The two primary outcomes were 1) treatment noncompletion and 2) receiving shorter RT regimens. Regression models were adjusted for relevant sociodemographic and clinical factors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The analytic cohort was comprised of 143,379 patients [White, n = 140,656 (98.10%); East Asian, n = 1,150 (0.80%); Southeast Asian, n = 925 (0.65%); Pacific Islander, n = 195 (0.14%); South Asian, n = 453 (0.32%)]. On multivariable analysis, Southeast Asian patients were associated with increased rate of noncompletion compared to White patients (Southeast Asian vs. White; OR: 1.55 [95% CI: 1.29-1.86], p &lt; 0.001). Geographic region of the treatment facility within the United States also was significant, as patients from the South Atlantic (OR: 1.32 [95% CI: 1.24-1.41], p &lt; 0.001), East North Central (OR: 1.09 [95% CI: 1.03-1.17], p = 0.007), East South Central (OR: 1.54 [95% CI: 1.41-1.68], p &lt; 0.001), and West South Central (OR: 1.14 [95% CI: 1.04-1.24], p = 0.005) regions all had higher rates of noncompletion in comparison to patients from New England. Distance from treatment facility, presence of comorbidities, and education attainment rates significantly impacted treatment noncompletion as well. Additionally, our study reports disparities in receipt of short course RT. Pacific Islander patients had substantially higher rates of SBRT (OR: 2.60 [95% CI: 1.10-6.16], p = 0.030) compared to White patients, while Hispanic patients had lower rates of SBRT (OR: 0.48 [95% CI: 0.40-0.57], p &lt; 0.001). Furthermore, receiving treatment in urban (OR: 0.68 [95% CI: 0.61-0.76], p &lt; 0.001) and metro (OR: 0.50 [95% CI: 0.39-0.65], p &lt; 0.001) facilities was associated with reduced access to SBRT than facilities in rural areas. Patients who received treatment in the Middle Atlantic (OR: 3.28 [95% CI: 2.91-3.68], p &lt; 0.001), South Atlantic (OR: 2.72 [95% CI: 2.40-3.09], p &lt; 0.001), East North Central (OR: 1.53 [95% CI: 1.34-1.75], p &lt; 0.001), East South Central (OR: 3.07 [95% CI: 2.61-3.63], p &lt; 0.001), West North Central (OR: 2.35 [95% CI: 2.02-2.75], p &lt; 0.001), and Mountain (OR: 2.45 [95% CI: 2.01-2.97], p &lt; 0.001) regions of the United States had significantly higher rates of SBRT compared to patients from New England.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This analysis found that Southeast Asian patients had higher rates of RT noncompletion in compariso","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"792-804"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance.","authors":"Marco Oderda, Giulia Orlando, Giorgio Calleris, Giulia Capella, Luisa Delsedime, Eleonora Duregon, Paola Francia di Celle, Donatella Pacchioni, Ian Marc Bonapace, Zaibunnisa Zaibunnisa, Daniele D'Agate, Gabriele Montefusco, Claudia Filippini, Mauro Papotti, Paolo Gontero","doi":"10.1002/pros.24921","DOIUrl":"https://doi.org/10.1002/pros.24921","url":null,"abstract":"<p><strong>Background: </strong>An accurate estimation of progression risk in patients with prostate cancer (PCa) amenable to active surveillance (AS) is still an unmet need. Among available biomarkers, we considered Prolaris cell-cycle progression (CCP) test, \"triple hit\" phenotype (ERG overexpression, PTEN and prostein expression loss) and elevated expression levels of TMPRSS2-ERG gene fusions.</p><p><strong>Methods: </strong>We performed a case-control study, enrolling patients that entered the AS programme at our tertiary referral Institution. Men subsequently undergoing radical prostatectomy for progression were considered as \"cases\", while men still on AS at the end of the follow-up period were labeled as \"controls\". CCP test, triple hit and TMPRSS2-ERG expression analyses were performed on tumoral tissue retrieved from biopsies at enrollment. Their ability to distinguish \"cases\" and \"controls\" was evaluated. According to power analysis, the study required 40 patients.</p><p><strong>Results: </strong>Patients had comparable baseline characteristics. CCP test suggested to continue AS in 75% of controls and to undergo an active treatment in 75% of cases. CCP molecular score (HR 8.5, p = 0.02) was significantly associated with progression in multivariable logistic regression. No significant differences were found in terms of \"triple hit\" or TMPRSS2:ERG expression. IHC analysis was feasible only in 17 patients due to insufficient material.</p><p><strong>Conclusions: </strong>CCP test may be a useful tool to estimate the risk of progression in PCa patients and guide the decision between AS and active treatment. Triple hit phenotype or TMPRSS:ERG fusion status was not associated with progression.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SBRT Boost in Prostate Cancer: Progress Made, Questions Remain.","authors":"Cem Onal, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler","doi":"10.1002/pros.24919","DOIUrl":"https://doi.org/10.1002/pros.24919","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA.","authors":"Penglu Yang, Bin Yang","doi":"10.1002/pros.24920","DOIUrl":"https://doi.org/10.1002/pros.24920","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the association between biochemical markers and prostate cancer (PCa) risk by analyzing patients with benign prostatic hyperplasia (BPH) and PCa. Additionally, the study sought to assess the diagnostic accuracy of a multimarker model compared to prostate-specific antigen (PSA) alone.</p><p><strong>Methods: </strong>A cross-sectional study was conducted with data from 2931 patients (1374 with BPH and 1557 with PCa) from the Prostate Cancer Data Set of the National Population Health Data Center. Biochemical markers, including PSA, apolipoproteins, lipid profiles, and metabolic markers (calcium and phosphate), were analyzed. Univariate and multivariate logistic regression analyses were performed to assess the associations with PCa risk. The diagnostic performance of the multimarker model was evaluated using receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>Total PSA levels were significantly higher in PCa patients, and the free/total PSA ratio was lower (p < 0.001). Apolipoprotein A1, LDL cholesterol, calcium, and phosphate were also significantly associated with PCa risk (p < 0.001). The multivariate logistic regression model, incorporating multiple markers, showed improved diagnostic accuracy (AUC 0.731, 95% CI: 0.713-0.749), with sensitivity of 68.4% and specificity of 65.8%.</p><p><strong>Conclusions: </strong>Combining multiple biochemical markers with PSA enhances the diagnostic accuracy for PCa, offering additional predictive value. This multimarker approach has the potential to improve PCa screening and reduce unnecessary biopsies.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}